Eleonora Calabretta

7PUBLICATIONS
38CO-AUTHORS
Haematological tumoursHaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 01, 2026
Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

|Jul 29, 2025
Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Edward Richardson, Clifton C Mo, Eleonora Calabretta

|Dec 16, 2024
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.

Björn Chapuy, Timothy Wood, Chip Stewart

|Oct 19, 2023
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

Eleonora Calabretta, Martina di Trani, Francesco Corrado

|May 17, 2022
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.

Eleonora Calabretta, Mehdi Hamadani, Pier Luigi Zinzani

|Apr 25, 2022
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.

Eleonora Calabretta, Anna Guidetti, Francesca Ricci

Pageof 2

Frequent Collaborators

5 joint publications

Carmelo Carlo-Stella

2 joint publications

Margaret A Shipp

1 joint publications

Michele Merli

1 joint publications

Enrico Derenzini